Register Now
You need to be registered to access all features and be part of the community.
Don't worry it's free !
Register Now
Lost Password
Lost your password? Please enter your username and email address. You will receive a link to create a new password via email.
Le GFEV a pour but d'aider à promouvoir la recherche, de diffuser des informations actualisées aux médecins et patients, d'organiser et de coordonner des études
Read More
Ratings : 42 %
Private Infusion Room 03 :
Ratings : 20 %
Groupe pharmaco-thérapeutique : anticorps monoclonaux, code ATC : L01X C02. Le rituximab se lie spécifiquement à l'antigène transmembranaire CD20, une
Read More
Ratings : 24 %
CheckOrphan NewsFlash, December 8, 2009 :
Ratings : 33 %
22 | La Lettre du Rhumatologue • No 372 - mai 2011 MISE AU POINT Le rituximab hors AMM en auto-immunité Off-label use of rituximab D. Cornec*, A. Saraux*
Read More
Ratings : 38 %
Case study Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease
Read More
Ratings : 36 %
Learn about indications, dosage and how it is supplied for the drug Rituxan (Rituximab).
Read More
Ratings : 52 %
Targeting BAFF for the treatment of AAV – Video abstract ID 67264 :
Ratings : 9 %
Arthritis treatment with Rituxan how it works and potential side effects :
Ratings : 27 %
Rituximab and Liposomal Doxorubicin Improve Progression-Free and Overall Survival When Added to Chem :
Ratings : 34 %
14. ME and Treatment :
Ratings : 55 %
Newlife Infusion Center Tour :
Ratings : 49 %
Rituxan Not Linked To Relief from Sjogren's After 24 Weeks :
Ratings : 12 %
Acumentis Rituximab CME :
Ratings : 72 %
Dr. Jennifer Brown on Idelalisib Plus Rituximab in CLL :
Ratings : 9 %
Cure For Multiple Sclerosis ? / Journal of Neuroimmunology / National Multiple Sclerosis Society :
Ratings : 74 %